Evercore ISI raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $76 from $68 and keeps an Outperform rating on the shares. The firm adjusted price targets in Smid-cap biotechnology as part of a research note discussing 2026 stock ideas. There is a “notable lengthening” of time horizons among investors, which is a positive sign for the broader small cap biotech markets, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MIRM:
- Mirum Pharmaceuticals’ Volixibat Study: A Potential Game-Changer for PBC Treatment
- Mirum Pharmaceuticals Holds 2025 Annual Stockholders Meeting
- Mirum Pharmaceuticals appoints Doug Sheehy as Chief Legal Officer
- Mirum Pharmaceuticals assumed with a Buy at H.C. Wainwright
- Mirum Pharmaceuticals price target raised to $77 from $73 at Raymond James